Company Name, Ticker, Industry, else..

Worst Performing Stocks In Healthcare Sector During The Last 5 Days

1 Day

Week

Current Month of March

30 Days

Current Quarter Q1 of 2025

90 Days

Ytd

12 Months

Shares improved by 0.46% on average, in Healthcare Sector during the last 5 days.

Here are the Worst performing stocks in Healthcare Sector.

ELEV

$0.2877

$-0.1938

-40.25%
Last 5 Days

ELEV

$0.2877

$-0.1938

-40.25%

Elevation Oncology inc

Elevation Oncology Inc shares declined -40.25% during the last 5 days.

Elevation Oncology Inc*s business model focuses on precision medicine and targeted therapies for rare and genomically defined cancers.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 16.408 mill.	$ - mill.	$ -44.485 mill.	57 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 16.408 mill.	$ - mill.	$ -44.485 mill.
Employees	Shares Outstanding	P/E
82	57 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ADAP

$0.2768

$-0.1783

-39.18%
Last 5 Days

ADAP

$0.2768

$-0.1783

-39.18%

Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc shares went down -39.18% during the last 5 days.

Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 424.781 mill.	$ 181.454 mill.	$ -44.516 mill.	1,535 mill.	-	Y/Y 354.13 %

Market Cap.	Revenues TTM	Net Income TTM
$ 424.781 mill.	$ 181.454 mill.	$ -44.516 mill.
Employees	Shares Outstanding	P/E
246	1,535 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 354.13 %	MRQ Y/Y - %

RMTI

$1.3408

$-0.3892

-22.50%
Last 5 Days

RMTI

$1.3408

$-0.3892

-22.50%

Rockwell Medical inc

Rockwell Medical Inc shares dropped -22.50% during the last 5 days.

Rockwell Medical Inc operates with a business model focused on developing, manufacturing, and marketing innovative medical products and therapies. The company aims to address critical health challenges by providing proprietary dialysis solutions and iron maintenance therapies. Their approach includes collaborating with healthcare providers to improve patient outcomes and enhance the standards of care in chronic kidney disease management.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 21.453 mill.	$ 101.484 mill.	$ -0.480 mill.	16 mill.	-	Y/Y 10.47 %

Market Cap.	Revenues TTM	Net Income TTM
$ 21.453 mill.	$ 101.484 mill.	$ -0.480 mill.
Employees	Shares Outstanding	P/E
56	16 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 10.47 %	MRQ Y/Y - %

INDP

$0.6595

$-0.1505

-18.58%
Last 5 Days

INDP

$0.6595

$-0.1505

-18.58%

Indaptus Therapeutics Inc

Indaptus Therapeutics Inc shares dropped -18.58% during the last 5 days.

Indaptus Therapeutics Inc*s business model focuses on developing and commercializing innovative therapies in the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 6.272 mill.	$ - mill.	$ -15.350 mill.	10 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 6.272 mill.	$ - mill.	$ -15.350 mill.
Employees	Shares Outstanding	P/E
50	10 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RNAZ

$0.6961

$-0.1187

-14.57%
Last 5 Days

RNAZ

$0.6961

$-0.1187

-14.57%

Transcode Therapeutics Inc

Transcode Therapeutics Inc shares dropped -14.57% during the last 5 days.

Transcode Therapeutics Inc*s business model revolves around developing innovative RNA-based therapies to treat a wide range of diseases. By leveraging their expertise in mRNA biology and proprietary drug delivery technology, they aim to create transformative treatments with optimized safety and efficacy profiles.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.310 mill.	$ - mill.	$ -14.927 mill.	0 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.310 mill.	$ - mill.	$ -14.927 mill.
Employees	Shares Outstanding	P/E
11	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PRPH

$0.3437

$-0.0473

-12.10%
Last 5 Days

PRPH

$0.3437

$-0.0473

-12.10%

Prophase Labs Inc

Prophase Labs Inc stock went down -12.10% during the last 5 days.

Prophase Labs Inc is a pharmaceutical company focused on developing and distributing consumer healthcare products.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 6.557 mill.	$ 12.087 mill.	$ -27.756 mill.	19 mill.	-	Y/Y -65.95 %

Market Cap.	Revenues TTM	Net Income TTM
$ 6.557 mill.	$ 12.087 mill.	$ -27.756 mill.
Employees	Shares Outstanding	P/E
15	19 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -65.95 %	MRQ Y/Y - %

RENB

$0.6612

$-0.0870

-11.63%
Last 5 Days

RENB

$0.6612

$-0.0870

-11.63%

Renovaro Inc

Renovaro Inc shares declined -11.63% during the last 5 days.

Renovaro Biosciences Inc is a biotechnology company that focuses on developing innovative therapies and technologies for regenerative medicine. Their business model involves conducting research and development, and partnering with pharmaceutical companies to bring their products to the market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 106.999 mill.	$ - mill.	$ -126.186 mill.	162 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 106.999 mill.	$ - mill.	$ -126.186 mill.
Employees	Shares Outstanding	P/E
-	162 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ELUT

$2.91

$-0.3600

-11.01%
Last 5 Days

ELUT

$2.91

$-0.3600

-11.01%

Elutia inc

Elutia Inc shares declined -11.01% during the last 5 days.

Elutia Inc operates as a technology company that specializes in the design and manufacturing of high-performance air purification systems. Their business model focuses on developing innovative and sustainable solutions to improve indoor air quality for various industries such as healthcare, education, hospitality, and more. By incorporating advanced technology and providing reliable products, Elutia aims to create a healthier and safer environment for their customers while also driving revenue through the sale and maintenance of their air purification systems.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 84.404 mill.	$ 23.707 mill.	$ -53.949 mill.	29 mill.	-	Y/Y -3.15 %

Market Cap.	Revenues TTM	Net Income TTM
$ 84.404 mill.	$ 23.707 mill.	$ -53.949 mill.
Employees	Shares Outstanding	P/E
-	29 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -3.15 %	MRQ Y/Y - %

SCLX

$0.277

$-0.0323

-10.44%
Last 5 Days

SCLX

$0.277

$-0.0323

-10.44%

Scilex Holding Company

Scilex Holding Company stock went down -10.44% during the last 5 days.

Scilex Holding Company operates as a pharmaceutical company focused on the development and commercialization of prescription drugs. Through its business model, it aims to identify and acquire assets that have the potential to address unmet medical needs and improve patient outcomes. The company primarily focuses on developing innovative, differentiated products in the therapeutic areas of pain management and neurology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 35.169 mill.	$ 55.152 mill.	$ -87.747 mill.	127 mill.	-	Y/Y 42.69 %

Market Cap.	Revenues TTM	Net Income TTM
$ 35.169 mill.	$ 55.152 mill.	$ -87.747 mill.
Employees	Shares Outstanding	P/E
100	127 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 42.69 %	MRQ Y/Y - %

ADGM

$0.8184

$-0.0916

-10.07%
Last 5 Days

ADGM

$0.8184

$-0.0916

-10.07%

Adagio Medical Holdings inc

Adagio Medical Holdings Inc stock declined -10.07% during the last 5 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.622 mill.	$ 24.387 mill.	$ -57.252 mill.	1 mill.	-	Y/Y -99.59 %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.622 mill.	$ 24.387 mill.	$ -57.252 mill.
Employees	Shares Outstanding	P/E
-	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -99.59 %	MRQ Y/Y - %

INO

$1.8897

$-0.2103

-10.01%
Last 5 Days

INO

$1.8897

$-0.2103

-10.01%

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc shares dropped -10.01% during the last 5 days.

Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of immunotherapies for the treatment of various diseases, including cancers and infectious diseases. Their business model involves leveraging their proprietary platforms, such as DNA-based technology and electroporation, to design and develop novel vaccines and therapies which are then advanced through clinical trials and potential partnerships for further commercialization.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 51.311 mill.	$ - mill.	$ -107.254 mill.	27 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 51.311 mill.	$ - mill.	$ -107.254 mill.
Employees	Shares Outstanding	P/E
120	27 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ENSC

$3.5

$-0.3800

-9.79%
Last 5 Days

ENSC

$3.5

$-0.3800

-9.79%

Ensysce Biosciences Inc

Ensysce Biosciences Inc shares went down -9.79% during the last 5 days.

Ensysce Biosciences Inc is a biopharmaceutical company that operates on a business model centered around developing and commercializing novel therapies using their proprietary drug delivery technology, known as MedXPRESS?. This technology allows for precise control of drug release and enhanced delivery to target tissues, with a focus on improving therapeutic outcomes and patient compliance.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2.308 mill.	$ 4.577 mill.	$ -0.762 mill.	1 mill.	0.85	Y/Y 597.05 %

Market Cap.	Revenues TTM	Net Income TTM
$ 2.308 mill.	$ 4.577 mill.	$ -0.762 mill.
Employees	Shares Outstanding	P/E
9	1 mill.	0.85
Revenue Growth	Income Growth
MRQ Y/Y 597.05 %	MRQ Y/Y - %

KEQU

$44.96

$-4.7300

-9.52%
Last 5 Days

KEQU

$44.96

$-4.7300

-9.52%

Kewaunee Scientific Corporation

Kewaunee Scientific Corporation shares declined -9.52% during the last 5 days.

Kewaunee Scientific Corp operates as a global provider of laboratory furniture, fume hoods, and related equipment. Their business model revolves around designing, manufacturing, and installing these products for various industries including pharmaceutical, chemical, and healthcare. They aim to provide customized laboratory solutions while focusing on quality, safety, and compliance with industry standards.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 134.655 mill.	$ 219.459 mill.	$ 17.815 mill.	3 mill.	7.69	Y/Y 44.21 %

Market Cap.	Revenues TTM	Net Income TTM
$ 134.655 mill.	$ 219.459 mill.	$ 17.815 mill.
Employees	Shares Outstanding	P/E
400	3 mill.	7.69
Revenue Growth	Income Growth
MRQ Y/Y 44.21 %	MRQ Y/Y -45.40 %

INNV

$3.2

$-0.3100

-8.83%
Last 5 Days

INNV

$3.2

$-0.3100

-8.83%

Innovage Holding Corp

Innovage Holding Corp stock declined -8.83% during the last 5 days.

Innovage Holding Corp*s business model revolves around providing comprehensive managed care services to a large elderly population. Their services primarily encompass care management, coordination, and support for seniors, including provision of care plans, healthcare navigation, and home-based services. Innovage focuses on delivering personalized care and promoting independent living for seniors through their innovative healthcare programs.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 433.407 mill.	$ 806.613 mill.	$ -27.639 mill.	135 mill.	-	Y/Y 10.64 %

Market Cap.	Revenues TTM	Net Income TTM
$ 433.407 mill.	$ 806.613 mill.	$ -27.639 mill.
Employees	Shares Outstanding	P/E
2,350	135 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 10.64 %	MRQ Y/Y - %

RZLT

$3.08

$-0.2900

-8.61%
Last 5 Days

RZLT

$3.08

$-0.2900

-8.61%

Rezolute Inc

Rezolute Inc shares went down -8.61% during the last 5 days.

Rezolute Inc*s business model involves developing and commercializing innovative therapies, focusing on rare and severe chronic metabolic and orphan diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 215.415 mill.	$ - mill.	$ -71.134 mill.	70 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 215.415 mill.	$ - mill.	$ -71.134 mill.
Employees	Shares Outstanding	P/E
30	70 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

DBVT

$4.34

$-0.3850

-8.15%
Last 5 Days

DBVT

$4.34

$-0.3850

-8.15%

Dbv Technologies S a

Dbv Technologies S A shares went down -8.15% during the last 5 days.

Dbv Technologies S.A.*s business model focuses on developing and commercializing novel therapies using its proprietary Viaskin technology platform, which aims to desensitize patients with food allergies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 69.586 mill.	$ 12.514 mill.	$ -102.089 mill.	16 mill.	-	Y/Y -54.81 %

Market Cap.	Revenues TTM	Net Income TTM
$ 69.586 mill.	$ 12.514 mill.	$ -102.089 mill.
Employees	Shares Outstanding	P/E
95	16 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -54.81 %	MRQ Y/Y - %

IMMX

$1.78

$-0.1500

-7.77%
Last 5 Days

IMMX

$1.78

$-0.1500

-7.77%

Immix Biopharma Inc

Immix Biopharma Inc shares went down -7.77% during the last 5 days.

ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 52.376 mill.	$ - mill.	$ -22.042 mill.	29 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 52.376 mill.	$ - mill.	$ -22.042 mill.
Employees	Shares Outstanding	P/E
19	29 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

EDAP

$2.1655

$-0.1745

-7.46%
Last 5 Days

EDAP

$2.1655

$-0.1745

-7.46%

Edap Tms Sa

Edap Tms Sa stock went down -7.46% during the last 5 days.

Edap Tms Sa*s business model revolves around providing minimally invasive medical devices and solutions for the treatment of urological diseases, specifically focusing on advanced ultrasound technologies for the diagnosis and treatment of prostate cancer and kidney stones.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 80.116 mill.	$ 67.674 mill.	$ -23.719 mill.	37 mill.	-	Y/Y 9.64 %

Market Cap.	Revenues TTM	Net Income TTM
$ 80.116 mill.	$ 67.674 mill.	$ -23.719 mill.
Employees	Shares Outstanding	P/E
134	37 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 9.64 %	MRQ Y/Y - %

RLYB

$0.6799

$-0.0545

-7.42%
Last 5 Days

RLYB

$0.6799

$-0.0545

-7.42%

Rallybio Corporation

Rallybio Corporation shares went down -7.42% during the last 5 days.

Rallybio Corporation operates on a business model focused on developing transformative therapies for patients with severe and rare diseases. Their approach involves collaborating with leading academic institutions, leveraging breakthrough scientific discoveries, and utilizing advanced technologies to accelerate the development of novel treatments. Through strategic partnerships, Rallybio aims to bring these innovative therapies to market and improve the lives of individuals suffering from unmet medical needs.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 29.535 mill.	$ 0.600 mill.	$ -57.775 mill.	43 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 29.535 mill.	$ 0.600 mill.	$ -57.775 mill.
Employees	Shares Outstanding	P/E
-	43 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ADCT

$1.65

$-0.1200

-6.78%
Last 5 Days

ADCT

$1.65

$-0.1200

-6.78%

Adc Therapeutics Sa

Adc Therapeutics Sa stock declined -6.78% during the last 5 days.

Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 172.961 mill.	$ 123.485 mill.	$ -367.172 mill.	105 mill.	-	Y/Y -91.20 %

Market Cap.	Revenues TTM	Net Income TTM
$ 172.961 mill.	$ 123.485 mill.	$ -367.172 mill.
Employees	Shares Outstanding	P/E
192	105 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -91.20 %	MRQ Y/Y - %

INCR

$1.44

$-0.1021

-6.62%
Last 5 Days

INCR

$1.44

$-0.1021

-6.62%

Intercure Ltd

Intercure Ltd shares went down -6.62% during the last 5 days.

Intercure Ltd is a company that operates in the healthcare sector. Their business model focuses on providing innovative medical solutions and technologies to improve patient outcomes and quality of life. They likely collaborate with healthcare providers, research institutions, and pharmaceutical companies to develop and market their products.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 65.604 mill.	$ 355.553 mill.	$ -63.533 mill.	46 mill.	-	Y/Y -8.52 %

Market Cap.	Revenues TTM	Net Income TTM
$ 65.604 mill.	$ 355.553 mill.	$ -63.533 mill.
Employees	Shares Outstanding	P/E
450	46 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -8.52 %	MRQ Y/Y - %

INTS

$2.145

$-0.1450

-6.33%
Last 5 Days

INTS

$2.145

$-0.1450

-6.33%

Intensity Therapeutics Inc

Intensity Therapeutics Inc stock went down -6.33% during the last 5 days.

Intensity Therapeutics Inc*s business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 29.611 mill.	$ - mill.	$ -15.417 mill.	14 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 29.611 mill.	$ - mill.	$ -15.417 mill.
Employees	Shares Outstanding	P/E
7	14 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SHPH

$0.394

$-0.0260

-6.19%
Last 5 Days

SHPH

$0.394

$-0.0260

-6.19%

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc stock dropped -6.19% during the last 5 days.

Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company that operates on a business-to-business (B2B) model. They develop and manufacture a wide range of pharmaceutical products and then distribute them to other companies or medical institutions for further distribution or use. Their primary focus is on ensuring the quality and effectiveness of their products while partnering with other entities to ensure their widespread availability in the market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.939 mill.	$ - mill.	$ -9.187 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.939 mill.	$ - mill.	$ -9.187 mill.
Employees	Shares Outstanding	P/E
10	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ENLV

$1.07

$-0.0700

-6.14%
Last 5 Days

ENLV

$1.07

$-0.0700

-6.14%

Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd shares declined -6.14% during the last 5 days.

Enlivex Therapeutics Ltd*s business model focuses on developing and commercializing novel immune system therapies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 19.875 mill.	$ - mill.	$ -29.068 mill.	19 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 19.875 mill.	$ - mill.	$ -29.068 mill.
Employees	Shares Outstanding	P/E
29	19 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IVVD

$0.7599

$-0.0459

-5.70%
Last 5 Days

IVVD

$0.7599

$-0.0459

-5.70%

Invivyd Inc

Invivyd Inc stock declined -5.70% during the last 5 days.

Invivyd Inc is a company that operates on a particular business model to deliver its products or services, but without providing any further details.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 90.298 mill.	$ 25.384 mill.	$ -169.925 mill.	119 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 90.298 mill.	$ 25.384 mill.	$ -169.925 mill.
Employees	Shares Outstanding	P/E
130	119 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

KALA

$6.8

$-0.4100

-5.69%
Last 5 Days

KALA

$6.8

$-0.4100

-5.69%

Kala Bio inc

Kala Bio Inc shares dropped -5.69% during the last 5 days.

Kala Pharmaceuticals Inc operates on a business model that revolves around the development and commercialization of innovative ophthalmic therapeutics to address unmet needs in eye care. Their approach focuses on utilizing their proprietary mucus-penetrating particle (MPP) technology to enhance drug delivery and improve patient outcomes. By leveraging partnerships and collaborations with industry stakeholders, Kala Pharmaceuticals aims to bring novel therapies to market and improve the standard of care for various eye diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 31.468 mill.	$ - mill.	$ -38.963 mill.	5 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 31.468 mill.	$ - mill.	$ -38.963 mill.
Employees	Shares Outstanding	P/E
27	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

CRL

$166.98

$-9.9600

-5.63%
Last 5 Days

CRL

$166.98

$-9.9600

-5.63%

Charles River Laboratories International inc

Charles River Laboratories International Inc stock declined -5.63% during the last 5 days.

Charles River Laboratories International Inc is a contract research organization (CRO) that provides essential services and support to the pharmaceutical, biotech, and medical device industries. They offer a wide range of research models, drug discovery and development services, safety assessments, and laboratory animal medicine to assist in the preclinical and clinical stages of drug development.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 8,596.965 mill.	$ 4,049.989 mill.	$ 25.291 mill.	51 mill.	1,053.32	Y/Y -1.08 %

Market Cap.	Revenues TTM	Net Income TTM
$ 8,596.965 mill.	$ 4,049.989 mill.	$ 25.291 mill.
Employees	Shares Outstanding	P/E
21,800	51 mill.	1,053.32
Revenue Growth	Income Growth
MRQ Y/Y -1.08 %	MRQ Y/Y - %

ACIU

$2.12

$-0.1200

-5.36%
Last 5 Days

ACIU

$2.12

$-0.1200

-5.36%

Ac Immune Sa

Ac Immune Sa stock went down -5.36% during the last 5 days.

Ac Immune Sa is a biopharmaceutical company that focuses on developing precision medicine to target neurological and neurodegenerative diseases. Their business model revolves around leveraging their proprietary technology platforms and partnerships with pharmaceutical companies to advance their drug discovery and development programs. Through licensing agreements and collaborations, they aim to bring innovative therapeutics to the market that address the urgent unmet needs in the field of neurology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 179.553 mill.	$ 14.801 mill.	$ -54.233 mill.	85 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 179.553 mill.	$ 14.801 mill.	$ -54.233 mill.
Employees	Shares Outstanding	P/E
83	85 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PMN

$0.6625

$-0.0375

-5.36%
Last 5 Days

PMN

$0.6625

$-0.0375

-5.36%

Promis Neurosciences inc

Promis Neurosciences Inc shares declined -5.36% during the last 5 days.

Promis Neurosciences Inc is a biotech company focused on developing innovative therapies for neurodegenerative diseases like Alzheimer*s and ALS. Their business model revolves around leveraging their expertise in neurosciences to discover and develop novel drug candidates that target protein misfolding, a key driver of these diseases. By translating their research into potential therapies, Promis Neurosciences aims to address unmet medical needs and improve the lives of patients suffering from neurodegenerative disorders.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 19.919 mill.	$ - mill.	$ -0.563 mill.	30 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 19.919 mill.	$ - mill.	$ -0.563 mill.
Employees	Shares Outstanding	P/E
20	30 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

EMBC

$12.79

$-0.6900

-5.12%
Last 5 Days

EMBC

$12.79

$-0.6900

-5.12%

Embecta Corp

Embecta Corp shares declined -5.12% during the last 5 days.

Embecta Corp is a company that operates on a business-to-business (B2B) model, providing services or products to other businesses rather than individual consumers.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ - mill.	$ 1,106.400 mill.	$ 58.200 mill.	- mill.	12.88	Y/Y -5.71 %

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ 1,106.400 mill.	$ 58.200 mill.
Employees	Shares Outstanding	P/E
4,045	- mill.	12.88
Revenue Growth	Income Growth
MRQ Y/Y -5.71 %	MRQ Y/Y - %

PLRX

$1.605

$-0.0850

-5.03%
Last 5 Days

PLRX

$1.605

$-0.0850

-5.03%

Pliant Therapeutics Inc

Pliant Therapeutics Inc stock declined -5.03% during the last 5 days.

Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 97.273 mill.	$ - mill.	$ -210.304 mill.	61 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 97.273 mill.	$ - mill.	$ -210.304 mill.
Employees	Shares Outstanding	P/E
35	61 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RLAY

$3.135

$-0.1550

-4.71%
Last 5 Days

RLAY

$3.135

$-0.1550

-4.71%

Relay Therapeutics Inc

Relay Therapeutics Inc stock declined -4.71% during the last 5 days.

Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 448.608 mill.	$ - mill.	$ -337.708 mill.	143 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 448.608 mill.	$ - mill.	$ -337.708 mill.
Employees	Shares Outstanding	P/E
280	143 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IPSC

$0.5605

$-0.0276

-4.69%
Last 5 Days

IPSC

$0.5605

$-0.0276

-4.69%

Century Therapeutics inc

Century Therapeutics Inc stock dropped -4.69% during the last 5 days.

Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 44.062 mill.	$ 6.589 mill.	$ -126.566 mill.	79 mill.	-	Y/Y 1,456.72 %

Market Cap.	Revenues TTM	Net Income TTM
$ 44.062 mill.	$ 6.589 mill.	$ -126.566 mill.
Employees	Shares Outstanding	P/E
75	79 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 1,456.72 %	MRQ Y/Y - %

ENGN

$4.91

$-0.2400

-4.66%
Last 5 Days

ENGN

$4.91

$-0.2400

-4.66%

Engene Holdings Inc

Engene Holdings Inc shares went down -4.66% during the last 5 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 250.297 mill.	$ - mill.	$ 69.047 mill.	51 mill.	3.31	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 250.297 mill.	$ - mill.	$ 69.047 mill.
Employees	Shares Outstanding	P/E
-	51 mill.	3.31
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y 129.82 %

IPA

$0.39

$-0.0177

-4.34%
Last 5 Days

IPA

$0.39

$-0.0177

-4.34%

Immunoprecise Antibodies Ltd

Immunoprecise Antibodies Ltd shares went down -4.34% during the last 5 days.

Immunoprecise Antibodies Ltd operates as a contract research organization specializing in the discovery and development of therapeutic antibodies to advance the treatment of various diseases. Through customized antibody solutions and a comprehensive portfolio of services, they offer support to pharmaceutical and biotechnology companies to accelerate their drug development processes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 9.998 mill.	$ 18.781 mill.	$ -20.818 mill.	26 mill.	-	Y/Y 18.65 %

Market Cap.	Revenues TTM	Net Income TTM
$ 9.998 mill.	$ 18.781 mill.	$ -20.818 mill.
Employees	Shares Outstanding	P/E
142	26 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 18.65 %	MRQ Y/Y - %

DMAC

$4.99

$-0.2200

-4.22%
Last 5 Days

DMAC

$4.99

$-0.2200

-4.22%

Diamedica Therapeutics Inc

Diamedica Therapeutics Inc shares went down -4.22% during the last 5 days.

Diamedica Therapeutics Inc*s business model focuses on developing and commercializing innovative therapies to improve patient outcomes in areas of unmet medical needs.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 203.293 mill.	$ - mill.	$ -24.444 mill.	41 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 203.293 mill.	$ - mill.	$ -24.444 mill.
Employees	Shares Outstanding	P/E
25	41 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SHLT

$2.45

$-0.1074

-4.20%
Last 5 Days

SHLT

$2.45

$-0.1074

-4.20%

Shl Telemedicine Ltd

Shl Telemedicine Ltd shares went down -4.20% during the last 5 days.

Shl Telemedicine Ltd*s business model revolves around providing remote healthcare services through telemedicine technology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 39.923 mill.	$ 57.075 mill.	$ -6.855 mill.	16 mill.	-	Y/Y -3.26 %

Market Cap.	Revenues TTM	Net Income TTM
$ 39.923 mill.	$ 57.075 mill.	$ -6.855 mill.
Employees	Shares Outstanding	P/E
135	16 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -3.26 %	MRQ Y/Y - %

SLDB

$4.725

$-0.2050

-4.16%
Last 5 Days

SLDB

$4.725

$-0.2050

-4.16%

Solid Biosciences Inc

Solid Biosciences Inc shares went down -4.16% during the last 5 days.

Solid Biosciences Inc is a biotechnology company focused on developing gene therapies for individuals with Duchenne muscular dystrophy (DMD).

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 192.547 mill.	$ - mill.	$ -124.697 mill.	41 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 192.547 mill.	$ - mill.	$ -124.697 mill.
Employees	Shares Outstanding	P/E
67	41 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

EOLS

$12.79

$-0.4900

-3.69%
Last 5 Days

EOLS

$12.79

$-0.4900

-3.69%

Evolus Inc

Evolus Inc shares declined -3.69% during the last 5 days.

Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 796.138 mill.	$ 371.973 mill.	$ -50.420 mill.	62 mill.	-	Y/Y 202.70 %

Market Cap.	Revenues TTM	Net Income TTM
$ 796.138 mill.	$ 371.973 mill.	$ -50.420 mill.
Employees	Shares Outstanding	P/E
50	62 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 202.70 %	MRQ Y/Y - %

ADIL

$0.71

$-0.0270

-3.66%
Last 5 Days

ADIL

$0.71

$-0.0270

-3.66%

Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc stock went down -3.66% during the last 5 days.

Adial Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing medications for the treatment of alcohol use disorder. Their business model revolves around conducting clinical trials, obtaining regulatory approvals, and marketing their products to healthcare professionals and potential patients.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 3.445 mill.	$ - mill.	$ -13.197 mill.	5 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 3.445 mill.	$ - mill.	$ -13.197 mill.
Employees	Shares Outstanding	P/E
11	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %